The FDA on September 2, 2022, approved IMFINZI® (Durvalumab) in combination with Gemcitabine and Cisplatin for adult patients with locally advanced or metastatic Biliary Tract Cancer (BTC). IMFINZI® is a product of AstraZeneca UK Limited.
Other Pages – Bottom Ad
Advertisement
Subscribe
